90 related articles for article (PubMed ID: 7916278)
1. Investigation on inactivated epidemic hemorrhagic fever tissue culture vaccine in humans.
Zhu ZY; Tang HY; Li YJ; Weng JQ; Yu YX; Zeng RF
Chin Med J (Engl); 1994 Mar; 107(3):167-70. PubMed ID: 7916278
[TBL] [Abstract][Full Text] [Related]
2. [Safety and immunogenicity of inactivated bivalent EHF vaccine in humans].
Liu W; Xu X; Ruan Y; Weng S; Liu W; Zhou W; Dong G; Gu H; Zhu Z; Xu Z
Zhonghua Liu Xing Bing Xue Za Zhi; 2000 Dec; 21(6):445-7. PubMed ID: 11860832
[TBL] [Abstract][Full Text] [Related]
3. [Serological surveillance on vaccine against hemorrhagic fever with renal syndrome].
Gong ZY; Weng JQ; Zhao ZY; Chen YT; Zhu AG; Fu GM; Fang CF; Zhu ZY; Chen EF; Wang CZ; Wang W; Lei LH; Wang Z
Zhonghua Liu Xing Bing Xue Za Zhi; 2004 May; 25(5):400-2. PubMed ID: 15231163
[TBL] [Abstract][Full Text] [Related]
4. [Comparative study on antibody levels of vaccination group and control group after 4 years of immunized with type B inactivated vaccine against hemorrhagic fever with renal syndrome].
Ruan Y; Liu W; Xu X; Weng SQ; Shao SK; Zhou WQ; Teng Z; Gu HX; Zhu ZY; Xu ZY
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Sep; 15(3):274-6. PubMed ID: 11986705
[TBL] [Abstract][Full Text] [Related]
5. [A study on immunogenicity and safety of bivalent inactivated vaccine against hemorrhagic fever with renal syndrome].
Ruan Y; Xu X; Liu W; Deng X; Weng S; Zhou W; Wang Q; Chen L; Fang L; Xu Z; Yan Q; Liu W; Dong G; Gu H; Yu Y; Xu Z
Zhonghua Yu Fang Yi Xue Za Zhi; 1999 Nov; 33(6):340-2. PubMed ID: 11864504
[TBL] [Abstract][Full Text] [Related]
6. [Preventive effects of three kinds of inactive vaccines against epidemic hemorrhagic fever (EHF) after 5 years of vaccination].
Chen H; Tang L; Luo Z; Zhang J; Zhang Z; Hu M; Weng J; Liu W; Zhao T; Liu W
Zhonghua Liu Xing Bing Xue Za Zhi; 2000 Oct; 21(5):347-8. PubMed ID: 11860813
[TBL] [Abstract][Full Text] [Related]
7. [Passage adaptability of candidate strains for hemorrhagic fever with renal syndrome purified vaccine in Vero cells and their immunogenicity].
Chen W; Xue CF; Liu JQ; Li ZY; Fan YX; Xu L; Liao H
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Jun; 17(2):129-32. PubMed ID: 12869992
[TBL] [Abstract][Full Text] [Related]
8. Long-term immunogenicity and safety of inactivated Hantaan virus vaccine (Hantavax™) in healthy adults.
Song JY; Woo HJ; Cheong HJ; Noh JY; Baek LJ; Kim WJ
Vaccine; 2016 Mar; 34(10):1289-95. PubMed ID: 26826547
[TBL] [Abstract][Full Text] [Related]
9. [The changes in serum antibody level after immunization with HFRS vaccine].
Gong Z; Weng J; Zhao Z; Lan J; Chen Y; Lin C; Fu G; Zhu Z; Xia J; Ji Q; Xu J; Wang C; Yu X; Wang W; Fang C
Zhonghua Yu Fang Yi Xue Za Zhi; 2000 Nov; 34(6):351-3. PubMed ID: 11860948
[TBL] [Abstract][Full Text] [Related]
10. Immunization effect of purified bivalent vaccine to haemorrhagic fever with renal syndrome manufactured from primary cultured hamster kidney cells.
Dong GM; Han L; An Q; Liu WX; Kong Y; Yang LH
Chin Med J (Engl); 2005 May; 118(9):766-8. PubMed ID: 15899141
[No Abstract] [Full Text] [Related]
11. [Comparison of subclinical infection rates between vaccinated group with type I inactivated vaccine against hemorrhagic fever and controls].
Ruan Y; Xu X; Shao S; Tong Z; Weng S; Zhou W; Gu H; Zhu Z; Xu Z
Zhonghua Yu Fang Yi Xue Za Zhi; 1999 Sep; 33(5):308-10. PubMed ID: 11864500
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of HFRS vaccination against hemorrhagic fever with renal syndrome during 1999-2000 in Laiwu City].
Wei K; Xie Y; Yao Z
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Sep; 16(3):283-5. PubMed ID: 12665942
[TBL] [Abstract][Full Text] [Related]
13. A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome.
Boudreau EF; Josleyn M; Ullman D; Fisher D; Dalrymple L; Sellers-Myers K; Loudon P; Rusnak J; Rivard R; Schmaljohn C; Hooper JW
Vaccine; 2012 Mar; 30(11):1951-8. PubMed ID: 22248821
[TBL] [Abstract][Full Text] [Related]
14. [Study on a 10-year protective effects of vaccination against hemorrhagic fever with renal syndrome].
Gong ZY; Weng JQ; Lei JB; Fang CF; Chen EF; Wang Z; Chen ZB; Wang W; He F; Liu BY; Lin JF; Ding GQ
Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Dec; 28(12):1190-3. PubMed ID: 18476579
[TBL] [Abstract][Full Text] [Related]
15. [Analysis on the immuno-effects of two different Japanese encephalitis virus vaccines].
Guo W; Li L; Wu Z
Zhonghua Liu Xing Bing Xue Za Zhi; 1998 Apr; 19(2):97-9. PubMed ID: 10322719
[TBL] [Abstract][Full Text] [Related]
16. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
17. Mixing of M segment DNA vaccines to Hantaan virus and Puumala virus reduces their immunogenicity in hamsters.
Spik KW; Badger C; Mathiessen I; Tjelle T; Hooper JW; Schmaljohn C
Vaccine; 2008 Sep; 26(40):5177-81. PubMed ID: 18482782
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of inactivated vaccine containing cyto-hemagglutinin against epidemic hemorrhagic fever in rabbits.
Zhu ZY; Tang HY; Li YJ; Weng JQ; Fu GM
Chin Med J (Engl); 1989 Aug; 102(8):602-5. PubMed ID: 2576866
[TBL] [Abstract][Full Text] [Related]
19. Immune responses to inactivated vaccine in people naturally infected with hantaviruses.
Lu Q; Zhu Z; Weng J
J Med Virol; 1996 Aug; 49(4):333-5. PubMed ID: 8877768
[TBL] [Abstract][Full Text] [Related]
20. Japanese encephalitis DNA vaccine candidates expressing premembrane and envelope genes induce virus-specific memory B cells and long-lasting antibodies in swine.
Konishi E; Yamaoka M; Kurane I; Mason PW
Virology; 2000 Mar; 268(1):49-55. PubMed ID: 10683326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
